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Abstract: 
 
Functional gastrointestinal disorders (FGID) affect 1 in 4 Americans and are likely caused by 
dysfunction of the enteric nervous system (ENS). The chronic nature of FGID suggests gene 
therapy is a promising form of treatment and can be used to treat diseases such as Hirschrprung’s 
disease. In this study, we characterized transduction efficiency and distribution in the mouse 
myenteric plexus following intravenous (IV) injection of adeno-associated viral vectors (AAV) 
expressing green fluorescent protein (GFP). Neonatal (P1) mice were injected with AAV9 in the 
temporal vein and juvenile mice (P21) were injected in the tail vein. Mice were euthanized at 60-
90 days of age, and the myenteric plexus was examined. Immunohistochemical labeling of the 
myenteric plexus revealed GFP presence along the entire GI tract in injected mice. Neuronal 
transduction ranged from 21-57% depending on vector dose and GI region analyzed. GFP co-
localized with interneurons, excitatory and sensory myenteric neurons while GFP expression was 
absent in VIP, nNOS and glial cells. Neonate IV injections with AAV1, 5, and 6 containing GFP 
produced little to no transgene expression in the myenteric plexus. However, AAV8 showed 
significantly higher neuronal transduction compared to AAV9 injected mice. Collectively, these 
data demonstrate that enteric neurons are efficiently transduced by AAV8 and AAV9 following 
IV delivery. Thus, AAV8 and AAV9 can be used as possible treatments for ENS dysfunction by 
the expression of a transgene. 
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Introduction: 
Use of Adeno-associated Virus in Gene Therapy 
 Adeno-associated virus (AAV) vectors have been shown to be promising in gene therapy 
applications and are currently permitted for many clinical trails. In order for gene therapy to be 
successful, a viral vector needs to be safe, achieve efficient infection of target tissue, and 
establish either long-term or short-term gene expression. AAV is a non-pathogenic single-
stranded DNA parovirus with multiple serotypes, which increases its potential as a delivery 
vehicle for gene therapy application. There are three main components of the AAV genome, 
namely its inverted terminal repeats (ITR), rep gene, and cap genes (Daya and Berns, 2008). The 
rep gene allows for replication and the cap gene encapsidates the viral genome during 
replication. ITRs play a key role in DNA replication of the viral genome and integration into host 
cells. When engineering a recombinant AAV (rAAV) the rep and cap genes are removed leaving 
only the ITRs (Goncalves, 2005). An expression cassette including a promoter, transgene and 
poly A is then inserted in between the ITRs, allowing the transgene to be produced by an 
infected cell. The newly engineered viral genome is placed in the capsid of the AAV viral 
particle. This capsid is an outside protein coating, which will determine the serotype of the AAV 
vector and allows the virus to enter cells via different receptors (Choi et al., 2005, Wu et al., 
2006). 
 It has recently been discovered that some AAV serotypes cross the blood-brain barrier 
(BBB) and can result in therapeutic benefit in animal models of neurological disease (Foust et 
al., 2010, 2013; Fu et al., 2011; Ahmed et al., 2013; Garg et al., 2013; Haurigot et al., 2013). 
AAV serotype 9 (AAV9) has been well characterized within the central nervous system (CNS) 
and has shown to have robust transduction in the CNS of mice, rats, cats and non-human 
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primates (Duque et al., 2009; Tatom et al., 2009; Bevan et al., 2011). Additionally, serotypes 1, 6 
and 7, along with other serotypes, cross the BBB and produce transgene expression at varying 
levels within the CNS (Zang et al., 2011). AAV’s ability to transduce central nervous tissue 
following systemic deliver suggests that the peripheral nervous systems (PNS) is likely 
transduced as well. Gene delivery to the PNS and CNS can be beneficial for treating global 
neurological diseases.  
 
The Enteric Nervous System 
 The enteric nervous system (ENS) is located in the gut and operates independently of the 
CNS to coordinate the complex actions within the gastrointestinal (GI) tract. The ENS contains 
as many neurons as the spinal cord with neurotransmitter diversity comparable to the CNS 
(Gershon and Ratcliffe, 2004). These neurons, along with enteric glia, reside in ganglia that form 
neural plexuses within the gut. The ENS is divided into two nerve plexuses, namely the 
submucosal plexus and the myenteric plexus. The submucosal plexus is located between the 
mucosal and circular muscle layers and is responsible for the chemoreception, 
mechanoreception, and secretory functions within the gut as well as some aspects of motility. 
The myenteric plexus is home to enteric motor neurons and is located between the circular and 
longitudinal smooth muscle layers. The myenteric plexus is responsible for motility as a result of 
neuromuscular transmission to smooth muscle, resulting in peristalsis. Peristalsis is the 
coordinated contraction and relaxation of smooth muscle that propagates in a wave-like action to 
move contents through the gut. Impaired neuromuscular transmission results in severe GI 
dysfunction. Apart from enteric neurons, other cell types are also important for proper GI 
function.. For example, enteric glia are essential for maintaining homeostasis and regulating 
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neural circuit activity (Gulbransen and Sharkey, 2012) and interstitial cells of Cajal are 
pacemakers in the gut wall and are thought to mediate neurotransmission between enteric motor 
neurons and smooth muscle (Ward and Sanders, 2006). 
 
Methods: 
Intravenous Injection of AAV.  
 All studies used self-complementary AAV with a chicken β actin promoter expressing 
green fluorescent protein (scAAV-CB-GFP).  Postnatal day 1 (P1) neonatal pups were injected 
with 5e10 vg/ml of AAV serotypes 1, 5, 6, 8, or 9 expressing green fluorescent protein (GFP). 
Pups were anesthetized on wet ice and injected in the temporal face vein under a dissecting 
microscope. Pups were warmed and returned to their home cage with the dam. Mice were 
euthanized by transcardial perfusion 30-60 days post-injection for myenteric dissection. When 
comparing age of administration, neonatal pups were injected at a dose of 1e11 vg/ml. 
Juvenile mice (P21) were injected in the tail vein while restrained in an illuminated tail vein 
injection platform. Mice were injected with AAV9 expressing GFP for a final dose of 2x1012 vg 
and returned to their home cages. Mice were euthanized by transcardial perfusion 30-60 days 
post-injection for myenteric dissection.  
 
Dissection of the myenteric plexus. 
 Entire gastrointestinal tracts (stomach, duodenum, jejunum, ileum, cecum and colon) 
were removed from euthanized mice after a saline rinse. Each segment of the GI tract was then 
separated, opened, and pinned flat in a dissection dish. Tissues were fixed overnight at 4° in 
Zamboni’s fixative (paraformaldehyde and picric acid). The next day, tissues were rinsed of 
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fixative and the mucosal, submucosal, and circular muscle layers were removed to expose the 
myenteric plexus on the longitudinal muscle.  
 
Immunohistochemistry.   
Brain and Spinal Cord: CNS tissues were post-fixed in 4% paraformaldehyde, and brains 
were further dehydrated in 30% sucrose solution. Brains and spinal cords were sliced at 40µm, 
and incubated in blocking solution (10% normal donkey serum, 1% Trition-X 100 in PBS) for 
two hours at room temperature. Sections were then incubated in primary antibody, chicken anti-
GFP (1:2000), mouse anti-NeuN (1:200, neurons), or rabbit anti-GFAP (glial fibrillary acidic 
protein, 1:500), overnight at room temperature.  The next day sections were incubated with the 
appropriate fluorescent secondary (1:500) for two hours at room temperature, were mounted on 
slides and coverslipped.  
Myenteric plexus chemical coding: GI tissue was blocked for 1 hour in blocking solution 
(10% normal donkey serum, 0.5% Trition-X 100 in PBS) followed by primary antibody made in 
0.5% Triton-X 100 PBS at 4° overnight. For initial quanitifcation, primary antibodies included 
chicken anti-GFP (1:200) and mouse anti-HuD (1:50) to identify transduced neurons. The next 
day, tissue was incubated with the appropriate fluorescent secondary antibodies (1:200) at room 
temperature for 2 hours. Tissue was then rinsed, placed on slides and coverslipped. For further 
chemical coding tissues were incubated in appropriate primary antibody overnight at 4°C against 
green fluorescent protein (GFP; 1:500), HuD (1:25), S100 (1:200), choline acetyltransferase 
(ChAT; 1:50), vasoactive intestinal peptide (VIP; 1:200), neuronal nitric oxide synthase (nNOS; 
1:200), calretinin (1:200), or calbindin (1:200).  The next day, tissues were rinsed 4 times for 10 
minutes in PBS, and then incubated in appropriate secondary antibodies at 1:200 for 2 hours at 
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room temperature.  Antibody dilutent was 3% NDS, 0.5% Triton-X 100 in PBS. Tissues were 
then rinsed and coverslipped with 2.5% PVA/DABCO.  Fluorescent images were captured on an 
Olympus confocal imaging system. 
 
Quantification of AAV9 transduced neurons. 
HuD positive neurons (red) and GFP positive neurons (green) were counted under the 
microscope at 20x. GFP positive neurons represented the successfully transduced neurons, and 
percentages of transduction were calculated from the total amount of neurons present.  
 
Results: 
Transduction of the CNS 
 To investigate AAV serotype transduction of the CNS, neonatal (P1) mice were injected 
with 5e10 vg/ml of AAV serotypes 1, 5, 6, 8, or 9 expressing green fluorescent protein (GFP). 
Figure 1.	  
 
AAV Transduction in the Brain and Spinal Cord following intravenous injection. GFP 
immunofluorescence was detected in neurons (NeuN, cyan) and astrocytes (glial fibrillary acidic 
protein (GFAP), red) in the brains and spinal cords of AAV1 (A,F), AAV6 (C,H), AAV8 (D,I), and 
AAV9 (E,J) intravenously injected mice. No CNS transduction occurred in AAV5 (B,G) injected 
animals. Arrowheads indicate transduced neurons (co-labeling with NeuN) and arrows indicated 
transduced astrocytes (co-labeled with GFAP). Scale bars are 100µm.	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Mice were euthanized 30-
60 days post-injection and 
the brain and spinal cord 
slices were immunolabeled 
for GFP, NeuN and GFAP. 
Immunolabeling revealed 
CNS transduction in 
AAV1, AAV6, AAV8 and 
AAV9, injected mice with 
no transduction occurring 
in AAV5 injected mice 
(Figure 1). The most 
robust CNS transduction 
was observed following 
AAV8 and AAV9 
injection. 
 
Transduction within the Myenteric Plexus 
To investigate if various AAV serotypes could also transduce the myenteric plexus, 
neonatal (P1) mice were injected as described above. Mice were euthanized 30-60 days post-
injection and myenteric plexus was immunolabed for GFP and HuD. Immunolabeling revealed 
little to no transduction occurred following AAV1, AAV5 and AAV6 intravenous injection. 
However, robust transduction was seen in AAV8 and AAV9 injected mice (Figure 2). GFP 
Figure 2.
 
 
Transduction efficiency in the myenteric plexus is dependent on 
AAV serotype. Neonatal mice were intravenously injected with 
AAV1 (A), AAV5 (B), AAV6 (C), AAV8 (D), or AAV9 expressing 
GFP (E) (final dose 5x10
10
 GC/ml). Green fluorescent protein (GFP, 
green) immunofluorescence in the myenteric plexus of the colon 
reveled little to no GFP expression in neurons (HuD, red) following 
AAV1, AAV5, and AAV6 intravenous injection. Robust GFP 
expression was detected in neurons in AAV8 (D) and AAV9 (E) 
injected mice. Total counts of neurons in the myenteric plexus of the 
colon revealed that 19.7% ± 0.9 or 16.0% ± 0.2 of neurons were 
transduced in AAV8 and AAV9 injected mice, respectively (F, p 
<0.001). Scale bars are 100µm. 
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positive myenteric neurons in AAV8 and AAV9 injected mice were quantified. In AAV8 
injected mice, a total of 3029 HuD positive and 599 GFP positive neurons were counted from 91 
ganglia. In AAV9 injected mice, a total of 3366 HuD positive and 539 GFP positive neurons 
were counted from 90 ganglia. A t-test revealed that transduction in AAV8 injected mice was 
significantly higher than that of AAV9 injected mice [t(178)= 4.11, p < 0.001]. An average of 20.6 
± 1% of neurons were transduced in AAV8 injected mice compared to that of 15.8 ± 1% in 
AAV9 injected mice. 
 
AAV9 transduction of the myenteric plexus 
 It has previously been reported that age of AAV9 administration can have a bias for cell 
type transduction in the CNS (Foust et al. 2009). Intravenous injection of AAV9 in neonatal 
mice preferentially targets neurons where as astrocytes are targeted in juvenile injected animals. 
Figure 3. 
   
Green fluorescent protein (GFP) expression in the myenteric plexus following intravenous 
injection of AAV9 expressing GFP into neonatal mice. Intravenous injection of AAV9 into P1 mice 
resulted in GFP (green, A-F) expression in neurons (HuD, red, G-L) in the stomach (A, G, M), 
duodenum (B, H, N), jejunum (C, I, O), ileum (D, J, P), cecum (E, K, Q), and in the colon (F, L, R). 
Arrows in merged images (M-R) point to GFP expressing neurons. Arrowheads identify untransduced 
neurons. Scale bars are 100µm. 
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To determine if the same transduction bias occurred in the myenteric plexus, AAV9 was injected 
in neonatal (P1) and juvenile (P21) mice. Neonatal mice were injected in the temporal face vein 
with 1e11 vg of AAV9. Three weeks post-injection, immunolabeling of GFP and HuD revealed 
robust transduction within myenteric neurons. GFP expression was limited to myenteric neurons 
and no expression was seen in S100 positive enteric glia. GFP was detected in all sections of the 
gastrointestinal tract, including the stomach, duodenum, jejunum, ileum, cecum and colon 
(Figure 3).  
 
 Juvenile mice were injected in the tail vein with 2e12 vg of AAV9 on P21. As with the 
neonatal injected mice, immunolabeling of GFP and HuD revealed robust transduction within 
myenteric neurons throughout all regions of the gastrointestinal tract (Figure 4). GFP expression  
Figure 4.                
 
Green fluorescent protein (GFP) expression in the myenteric plexus following intravenous 
injection of AAV9 expressing GFP into juvenile mice. Intravenous injection of AAV9 into P21 mice 
resulted in robust GFP (green, A-F) expression in neurons (HuD, red, G-L) in the stomach (A, G, M), 
duodenum (B, H, N), jejunum (C, I, O), ileum (D, J, P), cecum (E, K, Q), and in the colon (F, L, R). 
Arrows in merged images (M-R) point to GFP expressing neurons. Arrowheads identify untransduced 
neurons. Scale bars are 100µm. 
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was again limited to myenteric neurons and no expression occurred in enteric glia. These data 
show that there is no cell type transduction bias (neurons versus glia) dependent on age of 
administration within the myenteric plexus of the ENS. Next, GFP expressing myenteric neurons 
in neonatal and juvenile injected mice (n = 3 in each group) were quantified (Figure 5).  
In neonatal mice, transduction ranged from ~25% to ~43% depending on the GI examined. The 
highest transduction occurred in the colon with 43.7 ± 2% of HuD+ neurons being GFP+. In 
juvenile mice, transduction ranged from ~42% to ~57%, with the highest transduction occurring 
in the ileum with 57.2 ± 3% of HuD+ neurons being GFP+.   
 
Chemical coding of transduced neurons  
Myenteric neurons can be classified as motor neurons, interneurons and sensory neurons 
(Furness et al., 2003). These neurons can be further categorized by their chemical coding, which 
Figure 5. 
    
Quantification of GFP expressing myenteric neurons.  Total transduced and untransduced 
neuron counts in each gastrointestinal region in mice injected either at P1 (neonates, n = 3) or P21 
(juveniles, n = 3). Transduction of HuD positive neurons ranged from ~25% to ~43% in 
neonatally injected mice. Transduction ranged from ~42% to 57% in juvenile injected mice. 
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is based on the chemical markers present 
within the cell (Costa et al., 1986; Lomax 
and Furness, 2000). To determine if AAV9 
preferinally transduced certain neuronal 
subtypes, the myenteric plexus of the colon 
was immunolabeled for GFP, HuD, and 
either calbindin, calretinin, ChAT, nNOS, or 
VIP (Figure 6).  GFP co-expression 
occurred in ChAT, calbindin and calretinin 
positive neurons, and transgene expression 
did not occur in nNos and VIP positive 
neurons. ChAT is indicative of  
excitatory motor neurons that project to 
circular and longitudinal muscle as well as 
ascending and descending interneurons 
(Harrington at el., 2010). Calbindin is 
commonly expressed in descending 
interneurons (Costa et al., 1986; Furness, 
2000) and calretinin is expressed in 
ascending interneurons (Bergner et al., 
2014). nNOS and VIP are expressed in 
inhibitory motor neurons that project to 
circular and longitudinal muscle (Furness, 
Figure 6. 
     
Chemical coding of transduced myenteric cells in the 
colon after systemic GFP expressing AAV9 injection. 
GFP expression (B, E, H, K, N, Q) was detected in 
choline acetyltransferase (ChAT, A, C) positive, 
calbindin positive (D, F), and calretinin positive (G, I) 
myenteric neurons and some intraganglioninc fibers. 
ChAT staining is indicative of excitatory motor neurons 
and ascending and descending projecting interneurons. 
Calbindin and calretinin calcium binding proteins are 
indicative of excitatory motor neurons and some classes 
of interneurons. Transduction was rare or completely 
absent in vasoactive intestinal peptide (VIP, J, L) 
positive or neuronal nitric oxide synthase (nNOS, M, O) 
positive cells. VIP and nNOS staining is associated with 
inhibitory motor neuron and descending interneurons. 
GFP did not co-localize with S100 positive glial cells (P, 
R). Arrows indicate co-expression while arrowheads 
indicate no GFP expression. Scale bars are 100µm. 
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2000). These data suggests that AAV9 has a bias towards neurons that are involved in excitatory 
signaling.  
 
Discussion: 
 Characterizing AAV transduction in the ENS is important for developing novel GI 
therapies. This study characterized the transduction efficiency of different AAV serotypes, 
namely AAV1, 5, 6, 8 and 9. Robust transduction was seen in the ENS after delivery of AAV8 
and AAV9. Intravenous AAV9, a viral serotype now being delivered by intravenous injection in 
a clinical trial (Mendell, J.R., 2014), showed no difference in enteric cell tropism following 
either neonatal or adult injection. This result is contradictory to what occurs in the CNS 
following intravenous injection in mice. These data suggest that AAV mediated therapy 
development is feasible for the gastrointestinal tract. AAV gene therapy has the potential to treat 
both diseases of the gut alone, such as FGIDs, but may also be important for treated 
gastrointestinal symptoms associated with classical neurological diseases such as Parkinson’s 
disease. Most applicable to these data presented is the ability to develop therapies for functional 
gastrointestinal disorders (FGIDs) that are caused by the dysfunction of the ENS and 
inflammation within GI tract. 
FGIDs are the most common GI disorders in the general public with estimates being that 
1 in 4 people in the U.S have one of these disorders (Talley, 2008; Parkman and Doma, 2006). 
FGID’s can be separated into two separate subgroups, one having psychological and social 
features and the second having more somatic dysregulation (Bennett et al., 1998), These features 
cause common symptoms such as altered bowel habits or stool forms, defecatory dysfunction, 
abdominal distension/bloating, nausea, early satiety and visceral pain (McLaughlin, 2008). 
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Symptomatic therapy development has been hindered because of heterogeneity of reported 
symptoms, no method of targeted delivery, and the limited understanding of the biological basis 
of FGIDs (McLaughlin, 2008).  FGID symptoms are currently treated with pharmacotherapies, 
dietary and lifestyle changes and no cure is available.  
 When considering AAV as a novel treatment for diseases of the gut, it is important to 
pinpoint the involvement of the ENS. Alterations in the ENS such as degeneration and functional 
impairment of enteric neurons are associated with uncoordinated motor activities that result in 
altered transit of intestinal content (Di Nardo et al., 2008). For example, Hirschprung’s disease 
(HSCR) occurs as a result of an absence of enteric neurons and ganglia in terminal regions of the 
gut, leading to tonic contraction of the affected segment, intestinal obstruction and distention of 
the proximal bowel (Heanue and Pachnis, 2007). HSCR is representative of the main genetic 
cause of functional intestinal obstruction and occurs in 1:5,000 live births (Amiel et al., 2008). 
Due to the genetic involvement in HSCR and the dysfunction occurring as a result of impaired 
enteric neurons, AAV can be seen as a promising treatment for the disease. The only current 
treatment for HSCR is surgical removal of the aganglionic section of the gut. Although this 
method is able to remove the affected portion of the gut, there are still life-long GI problems that 
include chronic constipation and soiling (Moore et al., 1996, Yanchar et al., 1999, Amiel et al. 
2008). Thus, incorporating a long-term expression of a transgene within the affected enteric 
neurons can help relieve these effects and regulate normal functioning within the gut.  
The most common gene mutations in HSCR are found within the RET gene and are identified in 
50% of familial and 15-20% of sporadic HSCR cases (Amiel et al., 2008, Di Nardo et al., 2008). 
There has been over one hundred RET mutations that have been described throughout the gene; 
these mutations include deletions, insertions, missense, nonsense and splicing mutations (Hofstra 
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et al., 2000, Attie et al., 1995, Angrrist et al., 1995). RET is a transmembrane receptor with a 
cadherin-like extracellular domain, a cysteine-rich region and an intracellular tyrosine kinase 
domain (Ceccherini et al., 1993). Deletion of RET in the mouse leads to complete intestinal 
aganglionosis (Schuchardt et al., 1994). Activation of the RET receptor occurs when a complex 
is formed with one of its ligands by dimerization, such ligands are those of glial cell-line-derived 
neurotrophic factor (GDNF) and its co-receptor GDNF family receptor α1 (GFRα1) (Heanue 
and Pachnis, 2007). Furthermore, there have been patients that have been identified that carry 
heterozygous mutations in GDNF (Angrist et al., 1995). This ligand/receptor complex is 
essential for normal ENS development and maintenance of both central and peripheral neurons 
(Heanue and Pachnis, 2007, Amiel et al., 2008). By inserting a RET transgene within AAV, we 
can establish a constant expression of non-mutated RET within enteric neurons and restore 
functioning of the ENS and relive the symptoms seen in surgically treated patients. 
 In summary, it is shown that enteric neurons can effectively be targeted for gene therapy 
following systemic delivery of AAV8 and AAV9. These data can lay a foundation for the 
possible treatment of HSCR along with other FGID’s and neurological disorders that exhibit GI 
dysfunction.  
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